Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial.
Leroux-Roels I, Prajeeth CK, Aregay A, Nair N, Rimmelzwaan GF, Osterhaus ADME, Kardinahl S, Pelz S, Bauer S, D'Onofrio V, Alhatemi A, Jacobs B, De Boever F, Porrez S, Waerlop G, Punt C, Hendriks B, von Mauw E, van de Water S, Harders-Westerveen J, Rockx B, van Keulen L, Kortekaas J, Leroux-Roels G, Wichgers Schreur PJ.
Leroux-Roels I, et al. Among authors: aregay a.
Lancet Infect Dis. 2024 Nov;24(11):1245-1253. doi: 10.1016/S1473-3099(24)00375-X. Epub 2024 Jul 25.
Lancet Infect Dis. 2024.
PMID: 39068957
Clinical Trial.